Skip to main content

People In The News : May 3, 2013

NEW YORK (GenomeWeb News) – Gina Costa is now senior director of genomic applications at Illumina. She joins Illumina from Life Technologies, where she was senior director of genetic analysis, working on development of the Ion Torrent and SOLiD sequencing technologies.

She has also held positions at Agencourt Bioscience and Roche's 454 Life Sciences.


Personalis has appointed Michael Fitzpatrick to vice president of worldwide sales. He joins the company from OpGen, where he was vice president of global sales and commercial development. He has also held positions at Codon Devices and spent 20 years at Applied Biosciences before it was bought by Life Technologies.


The new personal genomics firm Mapmygenome India, which launched this week, has named Genetic Alliance President and CEO Sharon Terry to serve on its scientific advisory board, along with Ravi Bathina. The company also named its board of directors, including Arjun Malhotra, co-founder of HCL Technologies and founder of Headstrong; Anula Jayasuriya, co-founder and managing director of the Evolvence India Life Science Fund; company CEO Anu Acharya; and Subash Lingareddy, founder, president, and CFO of Ocimum Biosolutions.


Bioinformatics firm Golden Helix has hired Andreas Scherer to be its new president and CEO.

Scherer has managed large global software services businesses, and he started his executive career at AOL/Netscape.

He will replace Former CEO Christophe Lambert, who will take on the new role of company chairman.


Transgenomic's Chief Commercial Officer Chad Richards has tendered his resignation, effective May 10, the company said in a filing with the US Securities and Exchange Commission this week. Transgenomic said it has not named a replacement.


Metamark Genetics announced that Shawn Marcell will succeed Michael Kauffman as the company's new president and CEO. Kauffman had been serving as the firm's interim executive director after Mark Straley resigned as president and CEO last year. Kauffman will remain on Metamark's board of directors.

Before joining Metamark as its CEO, Marcell was general manager of Hologic's Lifecodes subsidiary, which was acquired by Immucor. He has also headed commercial operations at Sequenom and served as president and CEO of Sequenom subsidiary SensiGen


Cepheid said in an SEC filing this week that company shareholders have voted to re-elect three members of its board of directors, including Thomas Gutshall, Cristina Kepner, and David Persing.


BioRad Laboratories stockholders have re-elected Louis Drapeau and Albert Hillman as class A directors, and Deborah Neff, Alice Schwartz, and Norman Schwartz as class B directors.


Exosome Diagnostics has named Kapil Dhingra to be chairman of its board of directors. Dhingra has been a member of the board since March, 2012.

He currently is member of KAPital Consulting, and he formerly was an executive at Hoffman La-Roche. He also worked at Eli Lilly and was a faculty member of the University of Texas MD Anderson Cancer Center.


Exact Sciences said this week that Thomas Carey has joined its board of directors. Carey is a member at Spencer Stuart, an executive search firm, where he heads global efforts to provide board services to healthcare companies. He formerly was a partner and co-head at Russell Reynolds Associates' global life sciences practice. He also has been an investment banker and CFO for public and private healthcare IT firms.


The University of Texas Medical School has named Theresa Koehler chair of the Department of Microbiology and Molecular Genetics. Koehler, who has been interim chair of the department since September 2011, is the Herbert L. and Margaret W. DuPont Distinguished Professor in Biomedical Science.


Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.